Physician profile
Jeffrey E Sager
NPI 1427031160
$6,081.30
in general payments reported to CMS, 2019-2025
22 companies · $543 in 2025
The $543 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $448 · 2021: $786 · 2022: $2,029 · 2023: $747 · 2024: $703 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,984.94 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,670.94 | 2019-2025 | Precision 1, Dailies, Total30 |
| Glaukos Corporation | $352.19 | 2019-2022 | |
| Abbvie INC. | $250.97 | 2022-2024 | Lumigan, Alphagan P, Vuity |
| Horizon Therapeutics Plc | $240.25 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $202.79 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $198.37 | 2024-2025 | |
| Optos, INC. | $185.69 | 2021-2022 | |
| Genentech USA, INC. | $136.56 | 2019 | |
| Maculogix, INC. | $129.36 | 2020 | |
| Rxsight INC | $127.99 | 2022-2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Apellis Pharmaceuticals, INC. | $124.99 | 2023 | |
| Coopervision INC. | $124.75 | 2020-2024 | Myday Contact Lens |
| Lkc Technologies, INC. | $90.72 | 2025 | |
| Topcon Healthcare, INC. | $75.46 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visionix USA, INC | $41.66 | 2022 | |
| Bausch & Lomb Americas INC. | $30.13 | 2022-2023 | Infuse |
| Tarsus Pharmaceuticals, INC. | $28.08 | 2025 | Xdemvy |
| Dompe US, INC. | $26.67 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $20.65 | 2024 | Tyrvaya, Ryzumvi |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| United Therapeutics Corporation | $18.74 | 2023 | Remodulin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Sager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.